Myc-transformed epithelial cells down-regulate clusterin, which inhibits their growth in vitro and carcinogenesis in vivo.
Effective treatment of malignant carcinomas requires identification of proteins regulating epithelial cell proliferation. To this end, we compared gene expression profiles in murine colonocytes and their c-Myc-transformed counterparts, which possess enhanced proliferative potential. A surprisingly short list of deregulated genes included the cDNA for clusterin, an extracellular glycoprotein without a firmly established function. We had previously demonstrated that in organs such as skin, clusterin expression is restricted to differentiating but not proliferating cell layers, suggesting a possible negative role in cell division. Indeed, its transient overexpression in Myc-transduced colonocytes decreased cell accumulation. Furthermore, clusterin was down-regulated in rapidly dividing human keratinocytes infected with a Myc-encoding adenovirus. Its knockdown via antisense RNA in neoplastic epidermoid cells enhanced proliferation. Finally, recombinant human clusterin suppressed, in a dose-dependent manner, DNA replication in keratinocytes and other cells of epithelial origin. Thus, clusterin appears to be an inhibitor of epithelial cell proliferation in vitro. To determine whether it also affects neoplastic growth in vivo, we compared wild-type and clusterin-null mice with respect to their sensitivity to 7, 12-dimethylbenz(a)anthracene /12-Otetradecanoylphorbol-13-acetate (DMBA/TPA)-induced skin carcinogenesis. We observed that the mean number of papillomas/mouse was higher in clusterin-null animals. Moreover, these papillomas did not regress as readily as in wild-type mice and persisted beyond week 35. The rate of progression toward squamous cell carcinoma was not altered, although those developing in clusterin-null mice were on average better differentiated. These data suggest that clusterin not only suppresses epithelial cell proliferation in vitro but also interferes with the promotion stage of skin carcinogenesis.
Thomas-Tikhonenko
Andrei
A
Department of Pathobiology, University of Pennsylvania, Philadelphia, Pennsylvania 19104-6051, USA.
Viard-Leveugle
Isabelle
I
Dews
Michael
M
Wehrli
Philippe
P
Sevignani
Cinzia
C
Yu
Duonan
D
Ricci
Stacey
S
el-Deiry
Wafik
W
Aronow
Bruce
B
Kaya
Gürkan
G
Saurat
Jean-Hilaire
JH
French
Lars E
LE
D000818:Animals; D002455:Cell Division / Q000187:drug effects / Q000502:physiology; D002471:Cell Transformation, Neoplastic; D051152:Clusterin; D015536:Down-Regulation; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D016259:Genes, myc / Q000502:physiology*; D006023:Glycoproteins / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D006801:Humans; D015603:Keratinocytes / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D051379:Mice; D018345:Mice, Knockout; D018832:Molecular Chaperones / Q000096:biosynthesis / Q000235:genetics / Q000494:pharmacology / Q000502:physiology*; D011994:Recombinant Proteins / Q000494:pharmacology; D012878:Skin Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000473:pathology* / Q000517:prevention & control; D019700:Thrombospondin 1 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics
C495242:CLU protein, human; C495243:Clu protein, mouse; D051152:Clusterin; D006023:Glycoproteins; D018832:Molecular Chaperones; D011994:Recombinant Proteins; D019700:Thrombospondin 1